Peapack Gladstone Financial Corp Grows Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Peapack Gladstone Financial Corp raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 101,600 shares of the medical instruments supplier’s stock after buying an additional 2,057 shares during the quarter. Peapack Gladstone Financial Corp’s holdings in Becton, Dickinson and Company were worth $24,497,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its stake in Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after buying an additional 1,317,723 shares during the last quarter. Benson Investment Management Company Inc. raised its stake in shares of Becton, Dickinson and Company by 13.2% in the third quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock worth $5,380,000 after purchasing an additional 2,602 shares during the last quarter. Swedbank AB raised its stake in shares of Becton, Dickinson and Company by 1.8% in the third quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock worth $36,367,000 after purchasing an additional 2,729 shares during the last quarter. Nomura Asset Management Co. Ltd. raised its stake in shares of Becton, Dickinson and Company by 2.3% in the third quarter. Nomura Asset Management Co. Ltd. now owns 561,040 shares of the medical instruments supplier’s stock worth $135,267,000 after purchasing an additional 12,845 shares during the last quarter. Finally, Curi RMB Capital LLC raised its stake in shares of Becton, Dickinson and Company by 18.1% in the third quarter. Curi RMB Capital LLC now owns 84,873 shares of the medical instruments supplier’s stock worth $20,463,000 after purchasing an additional 13,030 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the sale, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. The trade was a 4.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on BDX. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI raised their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $283.50.

Becton, Dickinson and Company Stock Up 2.8 %

Shares of BDX stock opened at $227.17 on Friday. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The stock has a 50 day moving average of $231.25 and a 200 day moving average of $233.36. The stock has a market cap of $65.68 billion, a P/E ratio of 38.24, a P/E/G ratio of 1.64 and a beta of 0.41.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period last year, the company earned $3.42 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 6.9% compared to the same quarter last year. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be paid a $1.04 dividend. The ex-dividend date is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.83%. Becton, Dickinson and Company’s payout ratio is currently 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.